News Sentiment

IFRX sentiment intelligence

InflaRx N.V. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.05 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-8.5% over one week, +28.1% over four weeks, trend active, and near fair-value range.

Latest direct headline Negative

IFRX - InflaRx NV Revenue Breakdown

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -8.5% Price reacting lower
Trend fit Trend active 28.1% over four weeks
Fair value 23.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Stock Titan 11
Market source 9
TradingKey 6
GlobeNewswire 5
MSN 2
simplywall.st 2
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 17
Regulatory and legal 2
Analyst action 2
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Finviz Direct company coverage

IFRX - InflaRx NV Revenue Breakdown

This article provides a detailed financial breakdown for InflaRx NV (IFRX), including its market capitalization, enterprise value, various ratios like P/B and Quick Ratio, and performance metrics such as EPS growth rates and sales figures. It also lists insider and institutional

Tone
Negative 39/100
Event
Earnings
Published
05 Jul 2026 15:40
Source
Finviz
TradingView Direct company coverage

Price to earnings forward of InflaRx N.V. – NASDAQ:IFRX

This article provides "Price to earnings forward" data for InflaRx N.V. (NASDAQ: IFRX), a biotechnology company. It presents a specific financial metric for the company, indicating its valuation based on future earnings, but the value itself is redacted. The page structure sugges

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 03:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of InflaRx N.V. – MUN:IF0

This article provides financial information for InflaRx N.V. (IF0) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. The content is part of a larger financial data platform, TradingView, which offers various market tools and information.

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 02:09
Source
TradingView
MSN Direct company coverage

InflaRx regains Nasdaq compliance after shares trade above $1

InflaRx has successfully regained compliance with Nasdaq's minimum bid price requirement as its shares have traded above $1 for ten consecutive business days. This marks a positive development for the biotech company, which had previously received a deficiency notice from Nasdaq

Tone
Positive 77/100
Event
Market update
Published
02 Jul 2026 20:13
Source
MSN
TradingView Direct company coverage

Price to book forward of InflaRx N.V. – NASDAQ:IFRX

This article provides financial data for InflaRx N.V. (NASDAQ: IFRX), specifically focusing on its Price to Book Forward metric. The content highlights the stock's market status, financial overview, and general information available on the TradingView platform.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 22:40
Source
TradingView
Stock Titan Direct company coverage

InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback

InflaRx (IFRX) is reassessing its strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's Committee for Medicinal Products for Human Use recommendation to revoke Tavneos' marketing authorization. The company plans to engage with the EMA regarding its C5a-targe

Tone
Positive 64/100
Event
Market update
Published
30 Jun 2026 20:11
Source
Stock Titan
Quiver Quantitative Direct company coverage

InflaRx to Engage EMA on Vilobelimab and Izicopan Development Path in AAV

InflaRx N.V. intends to engage with the European Medicines Agency (EMA) to discuss the regulatory approval pathways for its therapies, vilobelimab and izicopan, for ANCA-associated vasculitis (AAV). This decision comes after the EMA's recommendation to revoke the marketing author

Tone
Positive 67/100
Event
Regulatory and legal
Published
30 Jun 2026 11:41
Source
Quiver Quantitative
Stock Titan Direct company coverage

EMA move on Tavneos pushes InflaRx to widen AAV plan in Europe

InflaRx is broadening its ANCA-associated vasculitis (AAV) strategy in Europe by evaluating regulatory paths for its drugs vilobelimab and izicopan, following the EMA’s recommendation to revoke Tavneos’ authorization. The company plans discussions with the EMA regarding both comp

Tone
Positive 71/100
Event
Regulatory and legal
Published
30 Jun 2026 11:12
Source
Stock Titan
GlobeNewswire Direct company coverage

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx is evaluating a broader strategy for ANCA-associated vasculitis (AAV) in Europe following the EMA's recommendation to revoke marketing authorization for Tavneos. The company plans to engage with the EMA regarding its anti-C5a antibody vilobelimab and oral C5aR inhibitor i

Tone
Positive 68/100
Event
Market update
Published
30 Jun 2026 11:12
Source
GlobeNewswire
TradingView Direct company coverage

Price to sales forward of InflaRx N.V. – NASDAQ:IFRX

This article provides financial data specifically focusing on the "Price to sales forward" for InflaRx N.V. (NASDAQ: IFRX). It likely presents a table or chart displaying the value, change, and percentage change of this metric over a specific period. The content is primarily a da

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 14:12
Source
TradingView
TradingView Direct company coverage

Price to book forward of InflaRx N.V. – GETTEX:IF0

This article provides access to the "Price to book forward" metric for InflaRx N.V. traded on GETTEX with the symbol IF0. It is a technical financial data point made by humans, likely for investors and analysts to evaluate the company. The content itself doesn't present the data

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 13:12
Source
TradingView
TradingView Direct company coverage

Price to sales forward of InflaRx N.V. – GETTEX:IF0

This article displays the "Price to sales forward" financial metric for InflaRx N.V. (GETTEX:IF0) on TradingView. It shows the period, value, and change information for this specific financial data point. The article is a snapshot from the financial analysis platform.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 01:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of InflaRx N.V. – NASDAQ:IFRX

The article focuses on the enterprise value to revenue forward metric for InflaRx N.V., traded on NASDAQ under the symbol IFRX. It appears to be a financial data snippet or a specific analytical view provided by TradingView, although no detailed financial figures are present in t

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 20:39
Source
TradingView
TradingView Direct company coverage

ETFs Investing in InflaRx N.V. Stocks

This article lists ETFs that hold InflaRx N.V. stocks, providing details such as market value, weight, issuer, and performance metrics. It highlights how these funds make stock investing more accessible and offer diversified opportunities with lower risk. The specific ETF mention

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 12:41
Source
TradingView
TradingView Direct company coverage

InflaRx N.V. Actuals & Estimates (HAM:IF0)

This article provides an overview of InflaRx N.V. (HAM:IF0) stock, including financial actuals and estimates, analyst forecasts, historical price data, and upcoming earnings dates. It also covers the company's revenue, net income, employee count, and information on how to trade i

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 04:10
Source
TradingView
MSN Direct company coverage

InflaRx NV (IFRX) price target decreased by 16.67% to 7.29

This article reports that the price target for InflaRx NV (IFRX) has been reduced by 16.67%, bringing it down to $7.29. The headline serves as the sole piece of information available from the provided content.

Tone
Negative 29/100
Event
Analyst action
Published
23 Jun 2026 15:10
Source
MSN
TradingKey Direct company coverage

InflaRx NV (IFRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for InflaRx NV (IFRX), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 8 analysts, the consensus is a "Buy" rating with an average target price of $8.00, suggesting a significant upsi

Tone
Positive 66/100
Event
Earnings
Published
18 Jun 2026 09:11
Source
TradingKey
TradingKey Direct company coverage

InflaRx NV (IFRX) Institutional Confidence

This article from TradingKey focuses on the institutional confidence score for InflaRx NV (IFRX), which currently stands at 3.00, unchanged from its previous score. The report details significant institutional shareholdings and recent changes in share percentages by various firms

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 09:09
Source
TradingKey
TradingKey Direct company coverage

InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for InflaRx NV (IFRX), focusing on business segments and regional contributions. As of the May 5, 2025 update, key relevant financial data regarding specific regional and business segment revenues has not yet been disclosed by the company

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:47
Source
TradingKey
TradingKey Direct company coverage

InflaRx NV (IFRX) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of InflaRx NV's (IFRX) financial health, noting its current score of 6.64 and ranking within the Biotechnology & Medical Research industry. It identifies the company's financial status as weak despite high operating efficiency. The report indicat

Tone
Negative 39/100
Event
Market update
Published
18 Jun 2026 05:40
Source
TradingKey
TradingKey Direct company coverage

InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of InflaRx NV's (IFRX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and lists no historical stock splits, indicating a lack of such events for IFRX within the recorded per

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

InflaRx NV (IFRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of InflaRx NV (IFRX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 6.81, ranking 208th in its industry, and is tradin

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:10
Source
TradingKey
Market source Direct company coverage

What Do Analysts Say About InflaRx N.V. (IFRX)?

Analysts are bullish on InflaRx N.V. (IFRX), with a consensus median price target of $8.95 and strong ratings, despite shares trading under $2. The positive sentiment follows upgrades from Raymond James and H.C. Wainwright, citing the izicopan program in ANCA-associated vasculiti

Tone
Positive 70/100
Event
Analyst action
Published
10 Jun 2026 18:22
Source
Market source
Investing.com Direct company coverage

InflaRx to develop izicopan for kidney disease treatment

InflaRx N.V. (NASDAQ:IFRX) is advancing the development of izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis and other complement-mediated kidney diseases. The biopharmaceutical company plans Phase 2 studies and open-label studies for various indications, e

Tone
Positive 67/100
Event
Market update
Published
04 Jun 2026 14:39
Source
Investing.com
Ad Hoc News Direct company coverage

InflaRx NV stock (NL0012661870): Nasdaq-listed biotech trades lower ahead of next earnings update

InflaRx NV's Nasdaq-listed stock (IFRX) experienced a 5% dip to around USD 2.28 in early June 2026, ahead of its next quarterly earnings update. Despite an average twelve-month price target of USD 7.00 from analysts earlier in the year, the current trading price reflects signific

Tone
Negative 37/100
Event
Earnings
Published
03 Jun 2026 01:01
Source
Ad Hoc News
Market source Direct company coverage

Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now

InflaRx N.V. (NASDAQ:IFRX) has received upgraded ratings and price targets from Raymond James and H.C. Wainwright, with analysts citing the company's izicopan program for ANCA-associated vasculitis (AAV) and its adjusted clinical focus. InflaRx plans to develop izicopan, an oral

Tone
Positive 72/100
Event
Market update
Published
31 May 2026 11:09
Source
Market source